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30 M.H. Abdullah et al.Measurements: Hemodynamic parameters, cardiac output, systemic vascular resistance, blood
gases, lactic acid, liver and kidney functions.
Results: All patients of both groups showed signiﬁcant decreases in MAP during or immediately
after the paracentesis process to reach mean values of 57 ± 1.4 and 58 ± 1.8 mmHg in terlipressin
or norepinephrine groups respectively. This was associated with drop in the SVR that reached mean
values of 445 ± 28 and 425 ± 20 dynes/sec/cm5 in both terlipressin and norepinephrine groups
respectively. At the 2nd day post operative there was signiﬁcant increase in serum creatinine values
in the norepinephrine group.
Conclusion: Terlipressin and norepinephrine successfully counteracted the post-paracentesis refrac-
tory hypotension and the drop of the systemic vascular resistance. It also showed the renal protec-
tive effects of terlipressin in the immediate postoperative period.
ª 2011 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Ascites is considered to be one of the major complications
in patients with end stage liver disease and portal hyperten-
sion [1]. Occasionally, some of those patients were pre-
sented to our emergency department with surgical acute
abdomen that required urgent abdominal surgery which
might be associated with inevitable rapid and relatively
complete evacuation of this ascitic ﬂuid with possible
occurrence of post-paracentesis-induced hypotension [2–4].
Some reports revealed that administration of albumin is
very beneﬁcial in the scenarios of therapeutic paracentesis
[5–7]. Other studies have shown that a marked decrease
in systemic vascular resistance (SVR) appears very early
after the mobilization of ascites [8–10], especially in pa-
tients who develop paracentesis induced circulatory dys-
function (PICD) and hypotension. Since the plasma
volume remains unchanged after paracentesis [11,12], an
accentuation of arterial vasodilatation, which is already
present in these patients, has been suggested to explain
the rapid decrease in SVR after paracentesis [10,13]. How-
ever, none of these reports were done intraoperatively dur-
ing emergency abdominal surgery.
Terlipressin acts via the vasopressin system, which may
be considered an important physiologic system for the regu-
lation of arterial blood pressure. This long-acting synthetic
analog of vasopressin has a half-life of 6 h and a higher vas-
cular selectivity for vascular receptors compared with vaso-
pressin [14], and Signiﬁcant vasoconstriction was clearly
demonstrated in experimental setting [15]. In addition to
its effects on microvascular blood ﬂow, terlipressin might re-
duce cardiac output via reﬂex mechanisms mediated through
glossopharyngeus baroreceptors reﬂex (aortic/carotid sinus
baroreceptors) [16].1.1. Aim of the study
The aims of this study were to compare between the intraoper-
ative use of terlipressin versus norepinephrine for the manage-
ment of paracentesis induced refractory hypotension not
responding to colloid resuscitation or ephedrine in patients with
end-stage liver disease during emergency abdominal surgery
regarding the intraoperative hemodynamic parameters, meta-bolic parameters ﬂuid requirements, post operative liver and re-
nal functions.
2. Patient and method
2.1. Patients
This study was carried out in the National Liver Institute –
Menofeya University after approval from the local ethical
committee and informed consents from patients. Among 93
adult tense ascitic patients with end stage liver disease (Child
B–C) scheduled for emergency abdominal surgery were pro-
spectively included in the study between March 2008 and Au-
gust 2011. Of them 34 patients experienced refractory
hypotension during or shortly after the paracentesis process
after being stable after induction of anesthesia, hence they
were randomized through closed envelops and analyzed in
the study. Paracentesis-induced hypotension was deﬁned as
mean arterial pressure (MAP) <60 mmHg or 30% drop of
MAP associated with the reduction of 10% or greater in
SVR than pre-paracentesis values not responding to albumin
and colloid replacement therapy [17,18]. The pre-paracentesis
value was determined by the mean of three sets of measure-
ments with 10 min intervals obtained 30 min before peritoneal
opening and drainage or spillage of the ascitic ﬂuid and only
patients who experienced hypotension in the presence of opti-
mized volume status were analyzed. Patients were excluded if
they had one of the following conditions: cardiac failure, sep-
sis, preoperative use of plasma expanders or paracentesis with-
in 1 week, preoperative ruptured or leaking hernia, evacuated
ascitic ﬂuid volume less than 5 L, preoperative beta blockers
and if there was primary renal dysfunction. The clinical char-
acteristics of the study groups are summarized in (Table 1).
2.2. Anesthetic technique
After preoxygenation, general anesthesia was induced with pro-
pofol 2 mg/kg IV, fentanyl 1 lg/kg IV and IV followed by
endotracheal intubation which was facilitated by rocuronium
1.2 mg/kg. All patients were mechanically ventilated to main-
tain an end-tidal carbon dioxide 35 ± 5 mmHg. Anesthesia
was maintained cisatracurium–isoﬂurane keeping entropy
reading (GE healthcare – Helsinki, Finland) between 40 and
Table 1 Demographic and data and patient characteristics.
T group (n= 17) N group (n= 17)
Age (years) 57.3 ± 4.1 61.5 ± 4.6
Gender (M/F) 13/4 12/5
Height (cm) 165.3 ± 7.2 167.2 ± 5.8
Weight (kg) 81.4 ± 5.7 82.5 ± 4.8
Child score: B/C 10/7 11 ± 6
Liver disease
HCV 15 15
HBV 1 1
HCV+ HBV 0 1
Alcoholic 1 0
Ascites removed (L) 7.7 ± 2.6 8.4 ± 1.9
T: terlipressin group; N: norepinephrine group; Data are presented
as mean ± SD or number of patients. There are no signiﬁcant
differences between the two groups (p-value > 0.05).
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increased. In contrast, if State entropy was in the recommended
range, but response entropy increases 5–10 units above it, this
was interpreted as a sign of uncovered nociception, and more
analgesic medication is required [18]. An arterial line was
placed in the left radial artery and central lines were inserted
in the right internal jugular vein with triple-lumen catheter.
Normothermia was maintained using ﬂuid warmer in addition
to forced warming air blanket (Bair Hugger; Arizant, United
Kingdom). During the postoperative period of the study, pa-
tients received oxygen via Venturi mask to maintain PaO2 at
greater than 100 mmHg.
2.3. Perioperative ﬂuid optimization
In all patients 500 mL of Ringer’s acetate was infused during
induction followed by a 2 mL/kg/hr continuous infusion. At
the stage of paracentesis simultaneous intravenous albumin
was administered (8 g/l of ascitic ﬂuid removed) using 20% hu-
man albumin solution [19]. Transesophageal doppler (TED)
was inserted after induction and to ensure euvolemic state,
for patients with corrected ﬂow time (FTc) of less than
350 ms which suggests hypovolaemia. The following protocol
was applied afterward [20]:
 If Stroke volume (SV) remains the same or increased and
FTc <350 ms – repeat the ﬂuid challenge.
 If SV increased by 10% and FTc >350 ms – repeat the ﬂuid
challenge till no increase in SV.
 If FTc >400 ms then no further ﬂuids are required till FTc
or SV decrease by 10%.
2.4. Protocol of the study
Patients included in study protocol were experienced refrac-
tory hypotension during or shortly after the process of acetic
ﬂuid spillage or paracentesis although optimized volume status
and also not or temporarily responding to ephedrine incre-
ments. They were randomized to receive either bolus dose of
terlipressin (1 mg over 30 min) followed immediately by a con-
tinuous infusion of 2 lg/kg/h (T group, n= 17) or norepi-nephrine infusion at a starting dose of 0.1 lg/kg/min (N
group, n= 17). Both infusions were progressively titrated to
increase MAP to the pre paracentesis values. The dose of ter-
lipressin was selected taking into account previous studies on
terlipressin [21]. In case of failure of both treatment and if
MAP was not restored (i.e., MAP was <60 mmHg or
>30% reduction of pre paracentesis value) for 10 min, pa-
tients received an intravenous bolus dose of 0.2 mg of epineph-
rine that can be repeated.
2.5. Measurements
1. Hemodynamic parameters including: Heart rate, electro-
cardiography (for any type of dysrhythmias), invasive arte-
rial blood pressure (radial artery catheter), central venous
pressure (CVP) and urine output.
2. TED data which include: stroke volume (SV), cardiac out-
put (COP), and systemic vascular resistance (SVR).
3. Metabolic parameters: Arterial blood gases and lactic acid
level in blood.
4. Liver and renal function parameters: Total bilirubin, ala-
nine aminotransferase (ALT), aspartate aminotransferase
(AST), international normalized ratio (INR) and serum
creatinine. Samples taken preoperatively and 2nd postoper-
ative day.
2.6. Statistical analysis
Data are shown as mean and standard deviation or fre-
quency. Statistical analysis was performed using the unpaired
Student’s t-test, the Mann–Whitney U test and chi square
test with Fisher correction. Data were statistically analyzed
using SPSS (statistical package for social science) program
version 17 for windows. A p-value < 0.05 was considered
to be signiﬁcant.
3. Results
During the inclusion period, 93 adult tense ascitic patients with
end stage liver disease (Child B-C) scheduled for emergency
abdominal surgery. Fifty nine patients were not included in
the study protocol for the following reasons: 21 patients did
not develop signiﬁcant hemodynamic changes during or after
the paracentesis process, 12 patients developed temporary
hypotension that responded to ephedrine increments, 15 pa-
tients were receiving beta blocker to control portal hyperten-
sion blockers, six had organic renal disease, and ﬁve did not
give consent to participate. Therefore, 34 patients whom devel-
oped refractory hypotension that did not respond to colloid
replacements or ephedrine increments were included in the
present study; 17 patients received terlipressin (T group), and
the other 17 patients received norepinephrine (N group). (Ta-
ble 1) shows characteristics of the enclosed patients in this
study. No signiﬁcant differences were detected between both
groups regarding clinical data, volume of ascites removed,
and mean arterial pressure at pre-paracentesis period. There
were no complications associated with either the administra-
tion of terlipressin, norepinephrine or the use of the TED.
During recovery and postoperative period, no patient experi-
Table 2 Hemodynamic data.
Before
paracentesis
After
paracentesis
End of surgery
HR (bpm)
T 85 ± 6.8 88 ± 5.7 88 ± 5.8
N 87 ± 4.9 90 ± 3.5 88 ± 4.4
MAP (mmHg)
T 90 ± 6.9 57 ± 1.4# 94 ± 6.3
N 95 ± 5.8 58 ± 1.8# 93 ± 4.9
CVP (mmHg)
T 9 ± 1.3 9 ± 1.5 9 ± 1.1
N 8 ± 1.3 9 ± 1.1 8 ± 1.2
SV (cc/beat)
T 101 ± 2.6 99 ± 9.6 99 ± 7.1
N 100 ± 6.8 101 ± 3.3 99 ± 4.9
COP (L/min)
T 8.5 ± 0.7 8.7 ± 0.9 8.8 ± 0.7
N 8.8 ± 0.6 9.1 ± 0.5 8.7 ± 0.6
SVR (dynes/sec/cm5)
T 795 ± 30 445 ± 28# 773 ± 20
N 784 ± 18 425 ± 20# 770 ± 36
T: terlipressin group; N: norepinephrine group; HR: heart rate;
MAP: mean arterial blood pressure; CVP: central venous pressure;
SV: stroke volume; COP: cardiac output; SVR: systemic vascular
resistance. All data presented as mean ± standard deviation.
# Signiﬁcance when compared with before paracentesis
(p< 0.05).
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Figure 1 Changes in the (MAP) mean arterial blood pressure in
both groups: before, after paracentesis and at the end of the
surgical procedure (T) terlipressin group; (N) norepinephrine
group.
Table 3 Metabolic parameters: blood gases, lactate, oxygen
consumption and CO2 production.
Before
paracentesis
After
paracentesis
End of surgery
pH
T 7.33 ± 0.4 7.32 ± 0.3 7.33 ± 0.2
N 7.34 ± 0.4 7.33 ± 0.3 7.34 ± 0.4
PaCO2
T 35.1 ± 1.8 34.8 ± 1.7 33.6 ± 1.6
N 36.6 ± 1.2 36.8 ± 1.6 35.8 ± 1.5
PaO2
T 146 ± 12.7 164 ± 14.6 162 ± 16.3
N 141 ± 13.8 167 ± 17.2 166 ± 18.1
HCO3 (meq/L)
T 22.8 ± 1.6 23.1 ± 1.9 23.1 ± 1.7
N 23.8 ± 1.7 22.7 ± 1.9 23.2 ± 1.7
Lactate (mg/dl)
T 11.1 ± 2.6 12.7 ± 2.8 12.1 ± 2.4
N 11.6 ± 2.3 12.2 ± 2.7 11.9 ± 2.5
T: terlipressin group; N: norepinephrine group. All data presented
as mean ± standard deviation. Normal range of lactic acid (4.5–
9.8 g/dl), p> 0.05 in all data.
32 M.H. Abdullah et al.enced bradycardia, tachycardia, hypertension or hypotension
that required medication. Terlipressin and norepinephrine
administrations did not alter the position of the ST segment
on the electrocardiogram and did not result in dysrrhythmias.Successful weaning of both drugs was done within 24 h
postoperatively.
However, all patients of both groups showed signiﬁcant de-
creases in MAP during or immediately after the paracentesis
process to reach mean values of 57 ± 1.4 and 58 ± 1.8 mmHg
in terlipressin or norepinephrine groups respectively (Table 2),
(Fig. 1). This was associated with drop in the SVR that reached
mean values of 445 ± 28 and 425 ± 20 dynes/sec/cm5 in both
terlipressin and norepinephrine groups respectively (Table 3)
(Fig. 2). Both blood pressure and systemic vascular resistance
were restored after either terlipressin or norepinephrine infu-
sions (Table 2) and (Figs. 1 and 2). There were no signiﬁcant
differences between the two groups regarding the COP (Table
2) and (Fig. 3), metabolic parameters which included: arterial
blood gases, lactate levels (Table 3), intraoperative ﬂuid man-
agement or the urine output (p-value > 0.05) (Table 4). Base-
line liver function tests and serum creatinine did not differ
between both groups (Table 5). However, at the 2nd day post
operative there was signiﬁcant increase in serum creatinine val-
ues in the norepinephrine group (p-value < 0.05) (Table 5).
Renal impairment, in the form of rise in serum creatinine to
more than 50% of baseline occurred in ﬁve patients in this
group, and eight patients in the norepinephrine group showed
serum creatinine level >1.5 mg/dL.4. Discussion
Since ascites raises the intra-abdominal pressure by displacing
the diaphragm and increasing intrathoracic pressure, Venous
return may be impaired because of inferior vena cava and right
chambers compression [22]. Moreover, compression of the
descending aorta increased the after load imposed on the left
ventricle [22]. Ascites evacuation has an immediate effect, be-
cause it improves cardiac performance through the Frank-
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Figure 2 Changes in the (SVR) systemic vascular resistance in
both groups: before, after paracentesis and at the end of the
surgical procedure (T) terlipressin group; (N) norepinephrine
group.
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Figure 3 Changes in (COP) cardiac output in both groups:
before, after paracentesis and at the end of the surgical procedure
(T) terlipressin group; (N) norepinephrine group.
Table 4 Infused volumes and urine output.
T group (n= 17) N group (n= 17)
Crystalloids 870 ± 330 890 ± 280
Colloids (ml) 740 ± 270 690 ± 240
FFPs (unit) 4.64 ± 1.36 4.88 ± 0.99
RBCs (unit) 1.47 ± 0.51 1.58 ± 0.71
Urine output (ml/hr) 86 ± 31 89 ± 34
T: terlipressin group; N: norepinephrine group; Data are presented
as mean ± SD. There are no signiﬁcant differences between the two
groups (p-value > 0.05).
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decrease in cardiac pressures is more evident for the right ven-
tricle, probably because of greater compliance of this chamber
[23]. This can explain that not all ascitic patients showed signif-
icant hypotension even with relatively rapid paracentesis pro-
cess [24]. The decrease in SVR was relatively less than those
patients who did not develop signiﬁcant hypotension and were
excluded from the present study.
Previous studies suggested that paracentesis could accentu-
ate the vasodilatation already present in cirrhotic patients with
ascites [25], and the present study conﬁrmed this hypothesis.
Immediately after paracentesis, a simultaneous decrease in
both MAP and SVR was observed in patients of both groups.
This drop in the two previously mentioned parameters might
be attributed to an increase in production of nitric oxide, a
powerful arterial vasodilator [26], which might be associated
with mechanical decompression of the IVC. In the present
work, since central venous pressure [27] and right atrial pres-
sure in cirrhotic patients with ascites are directly correlated
with intra-abdominal pressure [28,29], CVP was maintained
in all patients by using albumin infusion in a dose of 8 g/L
of ascitic ﬂuid removed [30]. However, there are no studies
in the literatures about intraoperative management of post-
paracentesis circulatory dysfunction and hypotension in pa-
tients with cirrhosis and tense ascites who undergo emergency
abdominal surgery. Under anesthesia, the sympathetic, renin-
angiotensin, and vasopressin systems are involved in the con-
trol of MAP. The agonists of the sympathetic system are used
as standard therapy to treat intraoperative hypotension. An a1
adrenergic agonist like norepinephrine is considered as more
effective than ephedrine in treating arterial hypotension. It
has a powerful vasoconstrictor activity, it constricts mesenteric
vessels and reduces splanchnic vasodilatation [31]. An alterna-
tive vasopressor like terlipressin may be effective in treating
hypotension in such patients because it acts on the vasopres-
sin- humoral vasopressor system, although the sympathetic
system is blunted by general anesthesia [32]. Eyraud et al, have
demonstrated that a bolus of terlipressin can restore MAP
with no concomitant impairment in the left ventricular func-
tion [32].
In our study, after establishment of norepinephrine infusion
or after the bolus dose of terlipressin, in association with the
restoration of MAP, we observed a signiﬁcant restoration of
the SVR and cardiac output. However, the vasoconstriction
after administration of those two vasoconstricting drugs could
cause, or at least worsen, hypoperfusion-related alterations in
organ function. Accordingly, the main ﬁnding of the study was
to investigate if there was signiﬁcant decrease in liver and kid-
ney functions, mainly linked to the potent vasoconstriction.
Duvoux et al. reported improvement in renal function and a
marked reduction in plasma active renin and aldosterone con-
centrations during norepinephrine treatment in patients with
hepatorenal syndrome [31]. They suggested that the haemody-
namic beneﬁt derived from norepinephrine-induced peripheral
vasoconstriction probably predominates over the action of
norepinephrine on the renal artery and results in improved re-
nal perfusion [31].
Another aim of the present study was to compare changes
in liver and kidney functions. The mean value for serum creat-
inine at 2nd postoperative day showed that (N) group dis-
played a signiﬁcantly higher serum creatinine than the (T)
group. Terlipressin enhances renal perfusion through increas-
Table 5 Liver and kidney function tests.
Preoperative 2 days postoperative
T group (n= 17) N group (n= 17) T group (n= 17) N group (n= 17)
Liver functions tests
Total bilirubin (mg/dl) 2.1 ± 1.1 2.2 ± 1.1 2.2 ± 1.2 2.3 ± 1.1
INR (ratio) 1.5 ± 0.11 1.4 ± 0.09 1.5 ± 0.1 1.5 ± 0.1
SGOT (U/ml) 93 ± 42.3 96 ± 38.3 95 ± 44.1 99 ± 41.9
SGPT (U/ml) 101 ± 47.8 99 ± 39.1 104 ± 37.1 106 ± 40.5
Renal function tests
Creatinine (mg/dl) 1.38 ± 0.1 1.38 ± 0.09 1.41 ± 0.09 1.65 ± 0.21*,#
T: terlipressin group; N: norepinephrine group; Values are mean ± SD; ALT: alanine aminotransferase; (AST): aspartate aminotransferase;
(INR) international normalized ratio.
* Signiﬁcance compared with the other group (p< 0.05).
# Signiﬁcance when compared with the preoperative value (p< 0.05).
34 M.H. Abdullah et al.ing both mean arterial pressure and effective arterial blood
volume [33]. Another mechanism is the increased diuresis med-
iated by the stimulation of V1a receptors [34]. However, there
were no signiﬁcant differences regarding the liver function tests
between the two studied groups. Finally, arterial pressure at
the end of surgery did not differ signiﬁcantly from baseline val-
ues in the norepinephrine or the terlipressin groups. These re-
sults, indicated that the overall response to treatment was
similar in the terlipressin and norepinephrine groups. How-
ever, because of the small sample size of the study groups, a
type II error cannot be excluded.
The present study had several limitations. We did not study
the inﬂuence of both drugs either terlipressin or norepineph-
rine on the integrity of renal tubular function by using newly
described sensitive markers such as urinary neutrophil gelatin-
ase-associated lipocalin and glutathione S-transferase for
hepatocellular integrity.
5. Conclusion
This research demonstrates that both drugs (terlipressin and
norepinephrine) successfully counteracted the post-paracente-
sis refractory hypotension and the drop of the systemic vascu-
lar resistance. It also showed the renal protective effects of
terlipressin in the immediate postoperative period for this cat-
egory of patients with normal kidney function who went into
emergency abdominal surgery However, we cannot judge with
conﬁdence whether our ﬁndings can be extended to patients
with moderate to severe renal impairment.Acknowledgment
This research work is attributed in the National Liver Insti-
tute, Menofeya University, Egypt. No sources of ﬁnancial sup-
port for the work.References
[1] Gine´s P, Quintero E, Arroyo V, Tere´s J, Bruguera M, Rimola A,
et al.. Compensated cirrhosis: natural history and prognostic
factors. Hepatology 1987;7:122–8.[2] Gine`s A, Ferna´ndez-Esparrach G, Monescillo A, Vila C,
Dome`nech E, Abecasis R, et al. Randomized trial comparing
albumin, dextran 70, and polygeline in cirrhotic patients with
ascites treated by paracentesis. Gastroenterology
1996;111:1002–10.
[3] Gine`s P, Tito´ L, Arroyo V, Planas R, Pane´s J, Viver J, et al.
Randomized comparative study of therapeutic paracentesis with
and without intravenous albumin in cirrhosis. Gastroenterology
1988;94:1493–502.
[4] Pozzi M, Osculati G, Boari G, Serboli P, Colombo P,
Lambrughi C, et al.. Time course of circulatory and humoral
effects of rapid total paracentesis in cirrhotic patients with tense,
refractory ascites. Gastroenterology 1994;106:709–19.
[5] Salerno F, Badalamenti S, Incerti P, Jempini S, Restelli B,
Bruno S. Repeated paracentesis and IV albumin infusion to treat
‘tense’ ascites in cirrhotic patients: a safe alternative therapy. J
Hepatol 1987;5:102–8.
[6] Tito´ LL, Gines P, Arroyo V, Planas R, Pane´s J, Rimola Al. Total
paracentesis associated with intravenous albumin in the
management of patients with cirrhosis and ascites. Gastroen-
terology 1990;98:146–52.
[7] Gines A, Ferna´ndez-Esparrach G, Monescillo A, Vila C,
Dome‘nech E, Abecasis R. Randomized trial comparing albu-
min, dextran 70, and polygeline in cirrhotic patients with ascites
treated by paracentesis. Gastroenterology 1996;111:1002–10.
[8] Panos MZ, Moore K, Vlavianos P, Chambers JB, Anderson JV,
Gimson AES. Single, total paracentesis for tense ascites:
sequential hemodynamic changes and right atrial size.
Hepatology 1990;11:662–7.
[9] Pozzi M, Osculati G, Boari G, Serboli P, Colombo P,
Lambrughi C. Time course of circulatory and humoral effects
of rapid total paracentesis in cirrhotic patients with tense,
refractory ascites. Gastroenterology 1994;106:709–19.
[10] Vila MC, Sola R, Molina L, Andreu M, Coll S, Gana J.
Hemodynamic changes in patients developing effective
hypovolemia after total paracentesis. J Hepatol 1998;28:639–45.
[11] Pinto PC, Amerian J, Reynolds TB. Large-volume paracentesis
in non edematous patients with tense ascites: its effect on
intravascular volume. Hepatology 1988;8:207–11.
[12] Salo J, Gines A, Gines P, Piera C, Jimenez W, Guevara M.
Effect of therapeutic paracentesis on plasma volume and trans-
vascular escape rate of albumin in patients with cirrhosis. J
Hepatol 1997;27:645–53.
[13] Ruiz-del-Arbol L, Monescillo A, Jimenez W, Garcı´a-Plaza A,
Arroyo V, Rode´s J. Paracentesis-induced circulatory
dysfunction: mechanism and effect on hepatic hemodynamics
in cirrhosis. Gastroenterology 1997;113:579–86.
Terlipressin versus norepinephrine to counteract intraoperative paracentesis induced refractory 35[14] Bernadich C, Bandi JC, Bosch J. Effects of F-180, a new
selective vasoconstrictor peptide compared with terlipressin and
vasopressin on systemic and splanchnic hemodynamics in rat
model of portal hypertension. Hepatology 1988;27:351–6.
[15] Scharte M, Meyer J, Van Aken H, Bone HG. Hemodynamic
effects of terlipressin (a synthetic analogue of vasopressin) in
healthy and endotoxemic sheep. Crit Care Med 2001;29:
1756–60.
[16] Cowley AW, Quillein EQ, Skelton MM. Role of vasopressin in
cardiovascular regulation. Fed Proc 1983;42:3170–6.
[17] Colla S, Vilaa MC, Molinab L, Gimeneza MD, Guarnerc C,
Sola R. Mechanisms of early decrease in systemic vascular
resistance after total paracentesis: inﬂuence of ﬂow rate of
ascites extraction. Eur J Gastroenterol Hepatol 2004;16:347–53.
[18] Viertio-Oja H, Maja V, Sarkela M. Description of the entropy
algorithm as applied in the datex- ohmeda S/5 entropy module.
Acta Anaesthesiologica Scand 2004;48:154–61.
[19] Tito L, Gines P, Arroyo V. Total paracentesis associated with
intravenous albumin management of patients with cirrhosis and
ascites. Gastroenterology. 1990;98(1):146–51.
[20] Tote SP, Grounds RM. Performing perioperative optimization
of the high risk patient. BJA 2006;97(1):4–11.
[21] Mukhtar A, Salah M, Aboulfetouh F, Obayah G, Samy M,
Hassanien A, et al. The use of terlipressin during living donor
liver transplantation: Effects on systemic and splanchnic
hemodynamics and renal function. Crit Care Med
2011;39(6):1329–34.
[22] Valeriano V, Funaro S, Lionetti R, Riggio O, Pulcinelli G, Fiore
P, et al.. Modiﬁcation of cardiac function in cirrhotic patients
with and without ascites. Am J Gastroenterol.
2000;95(11):3200–5.
[23] Pozzi M, Osculati G, Boari G, Serboli P, Colombo P,
Lambrughi C, et al. Time course of circulatory and humoral
effects of rapid total paracentesis in cirrhotic patients with tense,
refractory ascites. Gastroenterology 1994;106(3):709–19.
[24] Panos MZ, Moore K, Vlavianos P, Chambers JB, Anderson JV,
Gimson AE, et al. Single, total paracentesis for tense ascites:
sequential hemodynamic changes and right atrial size.
Hepatology 1990;11(4):662–7.[25] Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH,
Rode´s J. Peripheral arterial vasodilatation hypothesis: a
proposal for the initiation of renal sodium and water retention
in cirrhosis. Hepatology 1988;8:1151–7.
[26] Arroyo V, Gines P, Jimenez W, Rode´s J. Renal dysfunction in
cirrhosis. In: Rodes J, Benahmou JP, Bircher J, McIntyre N,
Rizzeto M, editors. Oxford textbook of clinical hepatology,
2nd ed., vol. 1. Oxford: Oxford University Press; 1999. p.
733–61.
[27] Knauer CM, Lowe HM. Hemodynamics in the cirrhotic patient
during paracentesis. N Engl J Med 1967;276:491–6.
[28] Guazzi H, Polese A, Magrini F, Fiorentini C, Olivari MT.
Negative inﬂuences of ascites on the cardiac function of cirrhotic
patients. Am J Med 1975;59:165–70.
[29] Luca A, Cirera I, Garcia-Pagan JC, Feu F, Pizcueta P, Bosch J,
et al. Hemodynamic effects of acute changes in intra-abdominal
pressure in patients with cirrhosis. Gastroenterology
1993;104:222–7.
[30] Singhn V, Kumar B, Nain CK, Singh B, Sharma N, Bhalla A,
et al. Noradrenaline and albumin in paracentesis-induced
circulatory dysfunction in cirrhosis: a randomized pilot study.
J Int Med 2006;260:62–8.
[31] Duvoux C, Zanditenas D, Hezode C. Effects of noradrenaline
and albumin in patients with type 1 hepatorenal syndrome: a
pilot study. Hepatology 2002;36:374–80.
[32] Eyraud D, Brabant S, Dieudonne N, Fleron MH, Godet G,
Bertrand M, et al. Treatment of intraoperative refractory
hypotension with terlipressin in patient chronically treated
with an antagonist of the renin-angiotensin system. Anesth
Analg 1999;88:980–4.
[33] Narahara Y, Kanazawa H, Taki Y. Effects of terlipressin on
systemic, hepatic and renal hemodynamics in patients with
cirrhosis. Gastroenterol Hepatol 2009;24:1791–7.
[34] Mutlu GM. Role of vasopressin in the management of septic
shock. Intens Care Med 2004;30:1276–91.
